339.30USDMkt Cap: 183.22B USDP/E: 23.61Last update: 2026-05-22
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthriti…
Industry Peers
Drug Manufacturers - Generalloading…
Indicators:|
Key Statistics
Company
Market Cap183.22B USD
Enterprise Value227.39B USD
Revenue (TTM)37.22B USD
Gross Profit24.71B USD
Net Income (TTM)7.71B USD
Revenue/Share69.12 USD
Last Price339.30 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees31.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS0311621009
Valuation
P/E (Trailing)23.61
P/E (Forward)14.37
PEG2.19
EV/EBITDA13.44
EV/Revenue6.11
P/S4.90
P/B19.82
EPS (TTM)14.37
EPS (Forward)23.48
52W Range
338.4017% of range343.80
52W High343.80 USD
52W Low338.40 USD
Profitability
Gross Margin67.25%
Oper. Margin33.80%
EBITDA Margin45.45%
Profit Margin20.98%
ROE89.06%
ROA8.51%
Growth
Revenue Growth5.80%
Earnings Growth4.40%
Cash Flow & Leverage
Operating CF9.96B USD
CapEx (TTM)1.86B USD
FCF Margin19.98%
FCF Yield4.06%
Net Debt45.29B USD
Net Debt/EBITDA2.68
Balance Sheet
Debt/Equity6.31
Current Ratio1.26
Quick Ratio0.85
Book Value/Sh17.03 USD
Cash/Share22.30 USD
Dividends
Fwd Div Rate10.08 USD
Trail. Div Rate9.660 USD
Div. Yield2.99%
5Y Avg Yield3.06%
Payout Ratio67.22%
Ex-Div DateMay 15, 2026
Pay DateJun 5, 2026
Splits
Last Split2:1
Split DateNov 22, 1999
Analyst Consensus
Rating2.5 (Buy)
Target (Mean)352.23 USD
Target Range200.00 USD – 427.00 USD
# Analysts30
Ownership
Shares Out.540.00M
Float538.23M
Insiders0.22%
Institutions85.43%
Short Interest
Short Ratio5.1d
Short % Float2.40%
Short % Out.2.40%
Shares Short12.97M
Short (prev mo.)13.98M
Technical
SMA 50344.43 (-1.5%)
SMA 200326.95 (+3.8%)
Beta0.43
S&P 52W Chg28.31%
Avg Vol (30d)1.30M
Avg Vol (10d)2.63M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—